News
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...
38m
Dear Doctor: Woman’s recent diagnosis has her on 6 new medications. ‘What about the side effects?’
DEAR DR. ROACH: I am a 52-year-old woman who was diagnosed with familial hypercholesterolemia in October 2024. I went through a cardiac workup for pain in my left arm and found this out.
The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...
Available webcasts will be accessible on Skye’s website.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback